FDA Approvals, News & UpdatesLeukemiaNewsworthy
October 2018 Vol 4 No 5 – October 17, 2018
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Page 1 of 6
Results 1 - 10 of 59

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.